The decision should help open the door to greater and more rapid access to psilocybin therapy for anxiety
Psychedelics
Small caps
Director Interviews
Cannabis
Psychedelics
Small caps
Small caps
Psychedelics
Psychedelics companies cheer as Canada grants landmark approval to four terminally ill patients to use psilocybin therapy
The decision should help open the door to greater and more rapid access to psilocybin therapy...
The New York City-based company has several projects in various stages from planning to ongoing...
The company is expecting significant growth in the second half of 2020 as it moves to launch its...
Algernon Pharmaceuticals, Clean Seed Capital, MamaMancini's Holdings, and Alpine 4 Technologies...
Joining Proactive this time out are environmental engineering company BioLargo; life sciences...
Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...
Pharma & Biotech
Valeo Pharma begins commercialization of Yondelis, a treatment for...
Pharma & Biotech
CytoDyn to submit request for pre-submission meetings in U.K. for...
Get our market previews and stories before the main networks.
Not just the FTSE. Read about
opportunities from the whole
equities market.
Hear directors at first-hand
or meet them in person at our events.
Watch IPOs and access on the same terms as the institutions.
